"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
Descriptor ID |
D017277
|
MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 2 | 0 | 2 |
2001 | 0 | 1 | 1 |
2002 | 1 | 2 | 3 |
2003 | 1 | 2 | 3 |
2004 | 1 | 2 | 3 |
2005 | 4 | 1 | 5 |
2006 | 0 | 5 | 5 |
2007 | 1 | 3 | 4 |
2008 | 2 | 2 | 4 |
2009 | 3 | 1 | 4 |
2010 | 2 | 4 | 6 |
2011 | 2 | 4 | 6 |
2012 | 2 | 1 | 3 |
2013 | 3 | 7 | 10 |
2014 | 1 | 3 | 4 |
2015 | 3 | 5 | 8 |
2016 | 3 | 2 | 5 |
2017 | 2 | 3 | 5 |
2018 | 3 | 4 | 7 |
2019 | 5 | 6 | 11 |
2020 | 2 | 8 | 10 |
2021 | 4 | 0 | 4 |
2022 | 0 | 3 | 3 |
2023 | 2 | 0 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Project Confirm: Accelerated Drug Approvals for CML-Response. Clin Cancer Res. 2024 01 05; 30(1):237-238.
-
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clin Cancer Res. 2023 06 13; 29(12):2179-2183.
-
Off-label is not always off-evidence: authorising paediatric indications for old medicines. Lancet Child Adolesc Health. 2023 06; 7(6):371-372.
-
Viewpoint: What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment? J Prev Alzheimers Dis. 2023; 10(3):344-345.
-
Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies. Trends Cancer. 2023 03; 9(3):237-249.
-
Accelerated approvals hit the target in precision oncology. Nat Med. 2022 10; 28(10):1976-1979.
-
New Drug Approvals for Sarcoma in the Last 5 Years. Surg Oncol Clin N Am. 2022 07; 31(3):361-380.
-
Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 05 04; 113(5):532-542.
-
Harmonising regulatory approval for antibiotics in children. Lancet Child Adolesc Health. 2021 02; 5(2):96-98.
-
Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.